Clinical trials: Metastatic Colorectal Carcinoma
Liver Metastasis Colon Cancer
Prospective Clinical Study of Intraoperative Assessment of Resection Margin of Colo-Rectal Cancer Liver Metastases
This prospective single arm double-blind study approved by the Ethics Committee of the institution, will be conducted on at the Oncology Institute of Vojvodina in Sremska Kamenica, Serbia.
- Trial name
- NCT04634526
- Where
- Serbia
- Volunteers
- 250 people
- Sponsor
- Oncology Institute of Vojvodina
Colorectal (Colon or Rectal) Cancer
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)
- Trial name
- NCT07462143
- Testing
- RC148 (Dose 1) plus Capecitabine and Oxaliplatin, RC148 (Dose 2) plus Capecitabine and Oxaliplatin
- Where
- 19 sites in China
- Volunteers
- 80 people
- Sponsor
- RemeGen Co., Ltd.
Recurrent Colon Cancer, Recurrent Rectal Cancer
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of capecitabine when given together with GTI-2040 and oxaliplatin in treating patients with locally advanced or metastatic colorectal cancer or other solid tumors.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
- Trial name
- NCT00084643
- Testing
- GTI-2040, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks…
- Trial name
- EGIA-003 (NCT06225843)
- Testing
- Sotevtamab, FOLFOX
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Alethia Biotherapeutics
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Colo-rectal Cancer
A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations
This is an open-label, unicentre, single-arm Phase 2 study of encorafenib and cetuximab as rechallenge treatment in patients with BRAF V600E-mutant metastatic colorectal cancer after previous therapy with BRAF inhibitors-based…
- Trial name
- REFISH (NCT07178717)
- Testing
- Rechalange with bevacizumab + encorafenib
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Metastatic Colorectal Cancer
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final…
- Trial name
- NCT01134640
- Where
- 15 sites in Taiwan
- Volunteers
- 286 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Colorectal Cancer
Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)
National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed…
- Trial name
- TIME (NCT02404935)
- Testing
- Cetuximab, FOLFIRI and cetuximab
- Where
- 47 sites in France
- Volunteers
- 139 people
- Sponsor
- UNICANCER
Colon Cancer, Rectal Cancer
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC).
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer, Colorectal Cancer (CRC)
- Trial name
- FRUITFUL (NCT07011576)
- Testing
- fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Colorectal Cancer (CRC)
Clinical Characteristics and Prognosis of Simultaneous Versus Delayed Resection for Synchronous Colorectal Liver Metastasis: A Nationwide Multicenter Study Utilizing Propensity Score Matching Analysis
Colorectal cancer (CRC) often metastasizes to the liver, with synchronous metastases observed in 20% of cases. Surgical resection is the primary treatment, but the impact of simultaneous and staged resections on clinical outcomes…
- Trial name
- NCT07082335
- Where
- China
- Volunteers
- 679 people
- Sponsor
- Shanghai 10th People's Hospital
Unresectable Metastatic Colorectal Cancer
A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy
This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients…
- Trial name
- NCT04866108
- Testing
- fruquintinib plus capecitabine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Friendship Hospital
Liver Metastasis Colon Cancer, Synchronous Neoplasm
Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer
This single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mCRC) using FOLFOXIRI neoadjuvant regimen and to assess the other outcome including…
- Trial name
- NCT05362825
- Testing
- Neo-adjuvant Chemotherapy FOLFOXIRI Regimen, synchronous resection surgery
- Where
- Vietnam
- Volunteers
- 89 people
- Sponsor
- Cho Ray Hospital
Colon Adenocarcinoma, Liver Metastasis Colon Cancer
LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis
This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT, partial or whole graft LT from deceased donors for unresectable CRLM.
- Trial name
- LIVERMORE (NCT05186116)
- Testing
- Living donor liver transplant, Split liver transplant, RAPID, DDLT
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Metastatic Colon Cancer
Development of Clinical and Biological Database in Colorectal Cancer
Creation of circulating cancer cell-lines and caracterisation of these cell-lines which will be collected before any treatment in patients with metastatic colon adenocarcinoma
- Trial name
- CIRCUS (NCT04186117)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 89 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Metastatic Colorectal Cancer
Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer
This study is to assess the efficacy and safety of Endostar combined with mFOLFOX6 in untreated metastatic colorectal cancer patients, and to find the markers that may predict the efficacy.
- Trial name
- NCT01832948
- Testing
- Endostar, Oxaliplatin, Folinic acid
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Colorectal Cancer, Liver Metastasis
Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)
This study is a multicenter, open-label, randomized ,controlled phase III study to compare preoperative and postoperative with FOFLOX4 chemotherapy and postoperative with FOFLOX4 chemotherapy in patients with resectable liver…
- Trial name
- NCT01035385
- Testing
- FOFLOX4
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Guangdong Provincial People's Hospital
Colorectal Neoplasms
Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients
This study makes an observation over the objective response rate of Apatinib and XELOX combination regimen in the first-line treatment of metastatic colorectal cancer.
- Trial name
- NCT02829385
- Testing
- Apatinib and XELOX combined treatment group
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Shoucheng Ma
Metastatic Colorectal Cancer
The Gene Profiles of Primary and Heterogeneous Metastases of Colorectal Cancer
The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents.In patients with synchronous metastatic colorectal…
- Trial name
- NCT04230018
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University